Abstract
Digestive abnormalities contribute significantly to the morbidity in cystic fibrosis as well as to the mortality, through their relations with the pulmonary part of the disease. Physiopathological consequences of the CFTR misfunction at different levels of the digestive tract (biliary and pancreatic secretions, digestion-absorption mechanisms) are not well understood. Even if pancreatic insufficiency is the most evident and critical problem, it is not the only one. That is the reason why pancreatic enzyme replacement therapy does not resolve all the digestive symptoms. Research is needed for a better understanding of digestive abnormalities in cystic fibrosis and their treatment.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
